Blog

• 
• 
• 
• 

One Vanderbilt Technology earned patent protection

Four new Vanderbilt technologies earn patent protection in November

9,826,904    System and method for detecting tissue surface properties

A team of scientists from Vanderbilt University, led by Professor John Wikswo, have won an R&D 100 Award for their MultiWell MicroFormulator device. The MultiWell MicroFormulator, developed at Vanderbilt and being commercialized by CN Bio Innovations, provides customized realtime formulation, delivery, and removal of cell culture media to each well of a 96-well plate for drug discovery, toxicology research, and personalized medicine.

Seven new Vanderbilt technologies earn patent protection in October.

9,803,758       Spool and body architectures for three-position directional control valves

Alzheimer's Disease Innovations

CTTC can help connect those interested in launch technology-based new ventures to programs provided by the state’s Launch TN – whose mission is to make Tennessee the best place in the Southeast to start and grow a business.  Launch TN’s resources for entrepreneurial researchers include a mentorship program, microgrants for SBIR/STTR grant-writing support, and an SBIR/STTR matching fund for young companies.  More information is available in the Launch TN Flyer or on LaunchTN.org.

Organ-on-a-Chip specialist CN Bio Innovations Limited announces a research collaboration with global biopharmaceutical company AstraZeneca to validate a new in vitro research tool that enables the high throughput evaluation of multi-drug dosing regimens.

CN Bio Innovations Limited announces that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research.

CN Bio Innovations Limited announces that it has licensed from Vanderbilt University three patents and applications, and software, covering microfluidics technologies relevant to the company’s Organs-on-Chips products and IP portfolio.

The agreement includes exclusive rights to applications claiming priority from US 15/191,092, as well as non-exclusive rights to US 9,618,129 and applications claiming priority from US 13/877,925.